Clinical outcomes among renal transplant recipients with pre-transplant weakly reactive donor-specific antibodies

Clinical Transplantation

Volumn 28, Issue 1, 2014, Pages 127-133

  Yoo, Peter S ^a   Bonnel, Alexander ^b   Kamoun, Malek ^b   Levine, Matthew H ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antibody; Cross match; Kidney; Rejection; Renal; Transplant

Indexed keywords

ALLOANTIBODY; DONOR SPECIFIC ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIBODY; CROSS-MATCH; KIDNEY; REJECTION; RENAL; TRANSPLANT;

ADULT; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HUMANS; ISOANTIBODIES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TISSUE DONORS; TREATMENT OUTCOME;

EID: 84892443535     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12289     Document Type: Article

References (23)

1. Lee PC, Terasaki PI, Takemoto SK et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002: 74: 1192.
2. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969: 280: 735.
3. Cecka JM, Kucheryavaya AY, Reinsmoen NL, Leffell MS. Calculated PRA: initial results show benefits for sensitized patients and a reduction in positive crossmatches. Am J Transplant 2011: 11: 719.
4. Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003: 75: 43.
5. Amico P, Honger G, Steiger J, Schaub S. Utility of the virtual crossmatch in solid organ transplantation. Curr Opin Organ Transplant 2009: 14: 656.
6. Lefaucheur C, Loupy A, Hill GS et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. JASN 2010: 21: 1398.
7. Patel AM, Pancoska C, Mulgaonkar S, Weng FL. Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 2007: 7: 2371.
8. Gibney EM, Cagle LR, Freed B, Warnell SE, Chan L, Wiseman AC. Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification. Nephrol Dial Transplant 2006: 21: 2625.
9. Bray RA, Gebel HM. Strategies for human leukocyte antigen antibody detection. Curr Opin Organ Transplant 2009: 14: 392.
10. Gupta A, Iveson V, Varagunam M, Bodger S, Sinnott P, Thuraisingham RC. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant? Transplantation 2008: 85: 1200.
11. Lefaucheur C, Suberbielle-Boissel C, Hill GS et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008: 8: 324.
12. Picascia A, Infante T, Napoli C. Luminex and antibody detection in kidney transplantation. Clin Exp Nephrol 2012: 16: 373.
13. Zeevi A, Lunz JG 3rd, Shapiro R et al. Emerging role of donor-specific anti-human leukocyte antigen antibody determination for clinical management after solid organ transplantation. Hum Immunol 2009: 70: 645.
14. Ellis TM, Schiller JJ, Roza AM, Cronin DC, Shames BD, Johnson CP. Diagnostic accuracy of solid phase HLA antibody assays for prediction of crossmatch strength. Hum Immunol 2012: 73: 706.
15. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713.
16. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003: 3: 708.
17. Loupy A, Suberbielle-Boissel C, Hill GS et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009: 9: 2561.
18. Amico P, Honger G, Mayr M, Steiger J, Hopfer H, Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009: 87: 1681.
19. Caro-Oleas JL, Gonzalez-Escribano MF, Gonzalez-Roncero FM et al. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation. Nephrol Dial Transplant 2012: 27: 1231.
20. Loupy A, Hill GS, Suberbielle C et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011: 11: 56.
21. Kraus ES, Parekh RS, Oberai P et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. Am J Transplant 2009: 9: 1826.
22. Bachler K, Amico P, Honger G et al. Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low-level donor-specific HLA-antibodies. Am J Transplant 2010: 10: 1254.
23. Lachmann N, Terasaki PI, Budde K et al. Anti-human leukocyte antigen and donor-specific antibodies detected by Luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009: 87: 1505.